Soo‐Youn Lee
성균관대학교 약학과 · 의학
이 교수의 연구실은 약물 대사 유전자 다형성, 개인 맞춤형 치료 전략 개발, 신경세포의 종양 유도 이동 메커니즘, 대사질환 및 우울증의 분자 기전을 중심으로 한 분야 간 융복합 연구를 수행하고 있습니다. 특히 CYP2D6 유전자 다형성 분석을 통한 약물 반응 예측, 암세포로 향하는 신경줄기세포의 이동 유도 인자 탐색, 그리고 대사물질과 호르몬 프로파일링을 통한 질병 진단 및 예후 평가에 초점을 맞추고 있습니다. 이는 임상적 적용이 가능한 정밀의료 기반의 생물학적 기전 규명을 목표로 하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
For clinical application of pharmacogenetic tests, quantitative prediction of enzyme activity based on accurate determination of genotype is essential. There has been limited information available on the genetic polymorphism of CYP2D6 in the Korean population. In this study, CYP2D6 genotypes were assessed in 400 Korean subjects. Twenty-eight different CYP2D6 alleles and 35 genotypes were detected. On the basis of the genotype determined, the frequency of poor metabolizers and ultrarapid metaboli
The current results indicated that a genome-wide pharmacogenomic approach is useful for identifying novel polymorphism predictors of severe OXCPN that may be used in personalized chemotherapy.
We conclude that COMP-Ang1 delayed the fibrotic changes in the kidney of diabetic db/db mice through its anti-inflammatory or metabolic effects.
Metabolism of amino acids, including ABA and glutamic acid, has the potential to contribute to understandings of pathogenesis and predictions of therapeutic response in MDD.
We recently reported that hNSCs (human neural stem cells) have the interesting characteristic of migration towards an intracranial glioma. However, the molecules and mechanisms responsible for tumour tropism are unclear. In the present study, we used microarray and proteomics analyses to identify a novel chemoattractant molecule, TIMP-1 (tissue inhibitor of metalloproteinase-1), secreted from human brain tumour tissues. We demonstrate that TIMP-1 significantly enhances hNSC adhesion and migratio
Our data showed that steroid profiling reduced the burden of follow-up exams by improving the positive predictive value of the CAH screening program. The use of steroid profiling as a second-tier test for positive CAH screening will improve clinical practice particularly in a tertiary care hospital setting where positive CAH screening from preterm neonates is frequently encountered.